Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for CINV in Gynecologic Cancers
NCT04232423Phase 3Completed
- Sponsor
- Ministry of Public Health
- Start
- Mar 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by Ministry of Public Health. Primary endpoint: Complete Response Rate of Chemotherapy-induced Nausea and Vomiting Prophylaxis at 5 days. Started Mar 2020; status: completed.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT04232423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232423.